> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Panel Rejects Correvio’s Vernakalant Over Safety
- URL: https://www.fdaweb.com/panel-rejects-correvios-vernakalant-over-safety/
- Published: 2019-12-11T12:00:00.000Z
- Updated: 2026-09-14T15:56:15.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5145705

FDA’s Cardiovascular and Renal Drug Advisory Committee has voted 11-2 against recommending approval of Correvio Pharma’s vernakalant for use to rapidly convert recent onset atrial fibrillation to sinus rhythm. Panel members were concerned about safety issues, which included bradycardia, ventricular arrhythmias and deaths recorded in clinical trials. FDA approval has been sought since 2006, but safety concerns caused the agency to previously reject it, and a clinical hold remains in effect after the death of a patient involved in an earlier clinical trial. The user fee review action target date is 12/24.